EA201790576A1 - Спироциклические ингибиторы катепсина с - Google Patents

Спироциклические ингибиторы катепсина с

Info

Publication number
EA201790576A1
EA201790576A1 EA201790576A EA201790576A EA201790576A1 EA 201790576 A1 EA201790576 A1 EA 201790576A1 EA 201790576 A EA201790576 A EA 201790576A EA 201790576 A EA201790576 A EA 201790576A EA 201790576 A1 EA201790576 A1 EA 201790576A1
Authority
EA
Eurasian Patent Office
Prior art keywords
katepsin
inhibitors
spirocyclic
spirocyclic inhibitors
cathepsin
Prior art date
Application number
EA201790576A
Other languages
English (en)
Other versions
EA031376B1 (ru
Inventor
Виктор Винтоняк
Маттиас Грауэрт
Марк Грундль
Александер Пауч
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201790576A1 publication Critical patent/EA201790576A1/ru
Publication of EA031376B1 publication Critical patent/EA031376B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению формулы Iгде А и Су имеют одно из значений, указанных в описании, и к их применению в качестве ингибиторов катепсина С, к содержащим его фармацевтическим композициям и к способам его применения в качестве средств для лечения и/или предупреждения заболеваний, связанных с активностью дипептидилпептидазы I, например респираторных заболеваний.
EA201790576A 2014-09-12 2015-09-08 Спироциклические ингибиторы катепсина с EA031376B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Publications (2)

Publication Number Publication Date
EA201790576A1 true EA201790576A1 (ru) 2017-08-31
EA031376B1 EA031376B1 (ru) 2018-12-28

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790576A EA031376B1 (ru) 2014-09-12 2015-09-08 Спироциклические ингибиторы катепсина с

Country Status (34)

Country Link
US (3) US9540373B2 (ru)
EP (2) EP3511331A1 (ru)
JP (2) JP2017526716A (ru)
KR (1) KR102510588B1 (ru)
CN (2) CN107074870B (ru)
AP (1) AP2017009733A0 (ru)
AU (1) AU2015314355B2 (ru)
BR (1) BR112017003433B1 (ru)
CA (1) CA2960916C (ru)
CL (1) CL2017000432A1 (ru)
CO (1) CO2017002268A2 (ru)
CY (1) CY1123033T1 (ru)
DK (1) DK3191487T3 (ru)
EA (1) EA031376B1 (ru)
ES (1) ES2749009T3 (ru)
HK (1) HK1255362A1 (ru)
HR (1) HRP20191756T1 (ru)
HU (1) HUE047208T2 (ru)
IL (1) IL250262B (ru)
LT (1) LT3191487T (ru)
MX (2) MX367316B (ru)
MY (1) MY188382A (ru)
NZ (1) NZ728684A (ru)
PE (1) PE20170438A1 (ru)
PH (1) PH12017500453B1 (ru)
PL (1) PL3191487T3 (ru)
PT (1) PT3191487T (ru)
RS (1) RS59444B1 (ru)
SA (1) SA517381064B1 (ru)
SG (1) SG11201701633SA (ru)
SI (1) SI3191487T1 (ru)
TW (1) TWI687424B (ru)
UA (1) UA118610C2 (ru)
WO (1) WO2016038007A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
NO2699580T3 (ru) 2014-01-24 2018-02-24
WO2016016242A1 (en) * 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
WO2019157050A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
MX2023006194A (es) * 2020-12-04 2023-06-09 Reistone Biopharma Company Ltd Inhibidor de molecula peque?a de catepsina c y uso medicinal del mismo.
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
CA2439415C (en) 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
JP2006527704A (ja) 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
CA2653662C (en) * 2006-06-01 2015-02-10 Sanofi-Aventis Spirocyclic nitriles as protease inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5240201B2 (ja) 2007-10-12 2013-07-17 富士通株式会社 Ｉｐ電話自動試験システム及び方法
MX2010006110A (es) 2007-12-12 2010-06-25 Astrazeneca Ab Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
JP2012526093A (ja) 2009-05-07 2012-10-25 アストラゼネカ・アクチエボラーグ 置換１−シアノエチルヘテロシクリルカルボキサミド化合物７５０
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
EP2841416A1 (en) 2012-04-27 2015-03-04 Glaxo Group Limited Novel compounds
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
BR112015007061B1 (pt) 2012-09-28 2022-10-04 Cancer Research Technology Limited Composto, composição farmacêutica e uso do composto
WO2014056942A1 (en) * 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
CN110041250A (zh) 2012-10-15 2019-07-23 Epizyme股份有限公司 经取代的苯化合物
MX358508B (es) 2012-10-16 2018-08-22 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
CN107936039A (zh) 2012-11-01 2018-04-20 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
HUE036739T2 (hu) 2012-12-21 2018-07-30 Plexxikon Inc Vegyületek és eljárások kináz modulációra, és azok indikációi
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SG11201504946VA (en) 2012-12-21 2015-07-30 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
JP6441831B2 (ja) * 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
ES2665619T3 (es) 2013-03-14 2018-04-26 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HUE053431T2 (hu) 2013-03-14 2021-07-28 Boehringer Ingelheim Int Szubsztituált 2-aza-biciklo[2.2.1]heptán-3-karbonsav-(benzil-ciano-metil)-amidok, mint a katepszin-C inhibitorai
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
DK3137136T3 (en) * 2014-04-29 2018-07-23 Carebay Europe Ltd DEVICE FOR ADJUSTING DEADLINE DEPTH
CN106660409A (zh) 2014-07-03 2017-05-10 普利司通美国轮胎运营有限责任公司 轮辋保护装置的侧壁装饰
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6531167B2 (ja) 2014-09-12 2019-06-12 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体
UA118610C2 (uk) * 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina

Also Published As

Publication number Publication date
CO2017002268A2 (es) 2017-06-20
HK1255362A1 (zh) 2019-08-16
JP6360961B2 (ja) 2018-07-18
MX2019009695A (es) 2019-10-07
DK3191487T3 (da) 2019-10-28
SA517381064B1 (ar) 2021-02-07
BR112017003433A2 (pt) 2017-11-28
RS59444B1 (sr) 2019-11-29
ES2749009T3 (es) 2020-03-18
USRE47636E1 (en) 2019-10-08
MX2017003156A (es) 2017-05-23
CN107074870A (zh) 2017-08-18
MY188382A (en) 2021-12-07
TWI687424B (zh) 2020-03-11
EA031376B1 (ru) 2018-12-28
AU2015314355A1 (en) 2017-02-16
NZ728684A (en) 2022-09-30
CN108047240A (zh) 2018-05-18
EP3511331A1 (en) 2019-07-17
JP2018044011A (ja) 2018-03-22
AP2017009733A0 (en) 2017-02-28
BR112017003433B1 (pt) 2023-11-14
CY1123033T1 (el) 2021-10-29
PH12017500453A1 (en) 2017-07-31
WO2016038007A1 (en) 2016-03-17
TW201625647A (zh) 2016-07-16
US9879026B2 (en) 2018-01-30
US20160075704A1 (en) 2016-03-17
CA2960916A1 (en) 2016-03-17
LT3191487T (lt) 2019-10-10
HRP20191756T1 (hr) 2019-12-27
SI3191487T1 (sl) 2019-12-31
IL250262B (en) 2020-03-31
JP2017526716A (ja) 2017-09-14
CA2960916C (en) 2023-03-07
PE20170438A1 (es) 2017-04-28
UA118610C2 (uk) 2019-02-11
PL3191487T3 (pl) 2020-03-31
KR20170054489A (ko) 2017-05-17
MX367316B (es) 2019-08-15
PT3191487T (pt) 2019-11-18
CN107074870B (zh) 2019-07-12
KR102510588B1 (ko) 2023-03-17
US20170073352A1 (en) 2017-03-16
EP3191487B1 (en) 2019-08-07
US9540373B2 (en) 2017-01-10
EP3191487A1 (en) 2017-07-19
HUE047208T2 (hu) 2020-04-28
PH12017500453B1 (en) 2017-07-31
SG11201701633SA (en) 2017-03-30
AU2015314355B2 (en) 2019-06-20
IL250262A0 (en) 2017-03-30
CN108047240B (zh) 2020-08-04
CL2017000432A1 (es) 2017-10-20

Similar Documents

Publication Publication Date Title
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201791576A1 (ru) Ингибитор jak
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201692480A1 (ru) Фармацевтическая композиция
EA201692003A1 (ru) Макроциклические производные пиримидина
MX2019001011A (es) Compuestos farmaceuticos.
EA201691881A1 (ru) Новые соединения
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM